|
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
<b>Conclusions:</b> In a long-term real-life setting, drug survival of UST is better than that of TNF-a inhibitors for both biologic-naive and biologic-experienced patients with psoriasis.
|
29848153 |
2019 |
|
Psoriasis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Psoriasis is associated with an overexpression in the involved skin of T-helper cell type 1 (Th1) cytokines, e.g. interferon (IFN) -gamma and tumour necrosis factor (TNF) alpha and relative underexpression of Th2 cytokines, e.g. interleukin (IL) -4 and IL-10.
|
11298547 |
2001 |
|
Psoriasis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Psoriasis (Ps) is an autoimmune disease characterized by keratinocyte hyperproliferation and chronic inflammation, with increased expression of tumor necrosis factor (TNF) and vascular endothelial growth factor (VEGF).
|
24587411 |
2014 |
|
Psoriasis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Psoriasis and Psoriasiform Eruptions in Pediatric Patients with Inflammatory Bowel Disease Treated with Anti-Tumor Necrosis Factor Alpha Agents.
|
28211161 |
2017 |
|
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Psoriasis can also be associated with other comorbidities such as joint disease, cardiovascular disease, and depression, which can add to the complexity of treatment.</p> <p>Adalimumab is a recombinant, fully human, monoclonal antibody against tumor necrosis factor alpha (TNF-α), which blocks the interaction of TNF with both of its cell-surface receptors, with high affinity and specificity.
|
28809993 |
2017 |
|
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Psoriasis is a systemic inflammatory disease with dramatic responses to TNF-α inhibitors.
|
29914850 |
2018 |
|
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Psoriasis is an immune-mediated disease where the IL-23/Th17 axis as well as TNF comprise main targets of biological therapy.
|
30307657 |
2018 |
|
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Psoriasis is a chronic, systemic inflammatory disease that in the moderate to severe forms may benefit of biologics, namely TNF and IL-12/23 and IL-17 inhibitors.
|
30515970 |
2019 |
|
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Psoriasis Associated with Tumor Necrosis Factor-Alpha Inhibitors in Children with Inflammatory Diseases.
|
31646743 |
2019 |
|
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Tumor necrosis factor-alpha in psoriasis and psoriatic arthritis: a clinical, genetic, and histopathologic perspective.
|
15251081 |
2004 |
|
Psoriasis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
TNF inhibition rapidly down-regulates multiple proinflammatory pathways in psoriasis plaques.
|
16081850 |
2005 |
|
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
TNF is critically involved in the pathogenesis of psoriasis.
|
21672030 |
2011 |
|
Psoriasis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
TNFα overexpression has been associated with several chronic inflammatory diseases, including psoriasis, lichen planus, rheumatoid arthritis, and inflammatory bowel disease.
|
24802997 |
2014 |
|
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
TNF-α plays a crucial role in psoriasis; therefore, TNF inhibition has become a gold standard for the treatment of psoriasis.
|
25384035 |
2014 |
|
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Tumor Necrosis Factor-α Inhibitor Use in Psoriasis Patients With a First-degree Relative With Multiple Sclerosis.
|
26267733 |
2015 |
|
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
TNF-α inhibitors could contribute to reduce the pathological imbalance between the Th<sub>1</sub> -Th<sub>17</sub> vs Th<sub>2</sub> axis in MSCs of patients with psoriasis.
|
27376466 |
2017 |
|
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Tumor necrosis factor-alpha inhibitors for the treatment of psoriasis patients with liver cirrhosis: A report of four cases with a literature review.
|
27451931 |
2017 |
|
Psoriasis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
TNF-α levels in patients with ichthyosis were increased only in those with Netherton syndrome but were much lower than in patients with psoriasis and those with AD.
|
27554821 |
2017 |
|
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Tumour necrosis factor (TNF)-α and interleukin (IL)-17 are key cytokines driving psoriasis and other inflammatory autoimmune diseases, and thus represent effective targets for anti-psoriatic therapy.
|
27747869 |
2017 |
|
Psoriasis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Tumor necrosis factor alpha (TNFα) gene -238G/A polymorphism (rs361525) is associated with psoriasis in several populations worldwide.
|
28093730 |
2017 |
|
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
TNFα-, IL-23- and IL-17-targeting drugs are highly effective in the treatment of psoriasis.
|
28109175 |
2017 |
|
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
TNF-α inhibitors have demonstrated efficacy both as monotherapy and in combination with disease-modifying anti-rheumatic drugs (DMARDs) in the treatment of chronic inflammatory immune-mediated diseases such as rheumatoid arthritis, Crohn's disease, ulcerative colitis, ankylosing spondylitis (AS), psoriasis (Ps) and/or psoriatic arthritis (PsA) and may be administered off-label to treat disseminated granuloma annulare, systemic lupus erythematosus and systemic sclerosis.
|
28837372 |
2018 |
|
Psoriasis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Tumor necrosis factor-α is an important pro-inflammatory cytokine having a key role in hosts defensive process of immune systems and its over expression led to a diverse range of inflammatory diseases such as Rheumatoid arthritis, Cronh's disease, psoriasis, etc.
|
29173945 |
2018 |
|
Psoriasis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
TNFα and NFκB were overexpressed in skin biopsies from EN, PG, and psoriasis.
|
29182760 |
2018 |
|
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
TNF inhibitors remain valuable tools in psoriasis therapy, and guidelines for their use may help clinicians use them effectively.
|
29334280 |
2018 |